PubMed Health⌕ Search

Biomedical subjects

A Horák

Publications and source records attributed to A Horák.

14 recordsLinked to original sources
PubMed2004

The phylogeny of diphyllobothriid tapeworms (Cestoda: Pseudophyllidea) based on ITS-2 rDNA sequences.

Phylogenetic analysis of sequences of the ITS-2 rRNA genes of 20 samples of pseudophyllidean cestodes of the family Diphyllobothriidae (Ligula, Digramma, Diphyllobothrium, and Schistocephalus) from different hosts and geographical regions revealed that: (1) the inclusion of ligulids (previously family Ligulidae) to the Diphyllobothriidae is correct; (2) Schistocephalus appears as the most basal taxon of the Diphyllobothriidae, well separated from Ligula and Digramma, thus supporting the validity of Schistocephalinae Dubinina, 1962; (3) Digramma belonged with samples of Ligula, thus suggesting its invalidity as a genus; and (4) isolates of Ligula, presumably belonging to Ligula intestinalis, are paraphyletic, indicating that this species may represent a complex of separate taxa. Our results indicate the necessity for a taxonomic revision of the family Diphyllobothriidae.

Animals↗
PubMed2001

Effects of zopiclone on blood glucose level, serum lipid concentration and clot lysis time in normoglycemic and normolipidemic rats.

In normoglycemic and normolipidemic rats the i.p. injection of zopiclone induced an acceleration of fibrinolysis in a dose-dependent bell shaped manner and various changes of the blood glucose level. Total lipids, total cholesterol and triglyceride serum levels remained unaffected by doses of 1.25, 2.5 and 15.0 mg/kg, with the exception of the medium dose (5.0 mg/kg) and the next dose (10.0 mg/kg) which lowered them very significantly.

Animals↗
PubMed2000

Acute effects of zopiclone on blood glucose level and serum lipids in hyperlipidemic rats. Interactions with PK 11195 and flumazenil.

UNLABELLED: Intraperitoneal administration of 5 mg/kg zopiclone a cyclopyrolone acting on the central benzodiazepine receptors was found to produce significant reduction of total lipids, total cholesterol and triglyceride in rats randered hyperlipidemic by intraperitoneal injection of Triton W-1339. Blood glucose level was also reduced. Flumazenil (10 mg/kg) potentiated the hypoglicemic effect of zopiclone but had no additional effect on serum lipids. PK 11195 (25 mg/kg) antagonized the hypolipidemic effects of zopiclone. IN CONCLUSION: 1. The central benzodiazepine receptors are not involved in the hypolipidemic activity of zopiclone. 2. The peripheral type benzodiazepine receptors are partly responsible, for the hypolipidemic activity of this cyclopirrolone. 3. The changes of blood glucose level induced by these drugs does not seem to be related to benzodiazepine receptors.

Animals↗
PubMed2000

Acute effects of zopiclone on blood glucose level and serum lipids in hyperlipidemic rats.

In rats rendered hyperlipidemic by ip administration of Triton WR-1339, the ip administration of zopiclone at doses of 1.25, 2.5, 5.0, 7.5, 10.0 and 15.0 mg/kg, a cyclopyrrolone acting upon the central benzodiazepine receptors, induces very significant reductions of total lipids, total cholesterol, and triglycerides, at nearly all of the doses. The most active dose was 5.0 mg/kg. The blood glucose level was diminished by doses of 1.25, 2.5, 7.5 and 15.0 mg/kg and it was not changed by the rest of the other doses.

Animals↗
PubMed1996

Effects of midazolam on glycemia and serum lipids in rats.

Midazolam administered ip. in albino rats (each group consisted from 10 animals rendered hyperdyslipidemic by the administration of Triton WR-1339) induced at most doses a significant reduction of glycemia (p < 0.001). However, the reduction of blood glucose level was outside of the dangerous level. Midazolam elicited also very significant decrease of the elevated serum lipids (p < 0.001). The pharmacological analysis of these phenomena by using the peripheral type benzodiazepine (BZD) receptors antagonist PK 11105, the central BZD receptor antagonist flumazenil and the purinergic P1 receptors antagonist aminophylline has shown that the effects on serum lipids were due, very probably to the stimulation of the peripheral type BZD receptors. Aminophylline seems to have the property to block the peripheral type BZD receptors. The effects on blood glucose level were very variable.

Aminophylline↗
PubMedDate not supplied

Influence of the acute intraperitoneal administration of tetrazepam on blood glucose level and serum lipids in normoglycemic and normolipidemic rats.

The acute i.p. administration of tetrazepam (5, 7.5, 15 mg/kg) in normoglycemic and normolipidemic rats induced an increase in blood glucose level, a delay of fibrinolysis (when administered at the first two doses) and variable changes of serum lipids. These results are different from those obtained in hyperlipidemic rats treated with tetrazepam.

Animals↗
PubMedDate not supplied

Effects of acute intraperitoneal administration of tetrazepam on blood glucose level and serum lipids in hyperlipidemic albino rats.

In rats rendered hyperlipidemic by the i.p. injection of Triton WR-1339, the i.p. administration of tetrazepam, a benzodiazepine (BZD) used mainly as a central myorelaxant, evoked significant reductions of serum lipids and blood glucose level. The dose-response curve was bell-shaped for serum lipids changes, whereas no clear dose-response relationship for blood glucose level modifications could be established. Tetrazepam was less active on serum lipids than other BZDs as diazepam or midazolam.

Animals↗
PubMedDate not supplied

Effects of lormetazepam on glycemia and serum lipids in hyperlipidemic rats.

Lormetazepam (N-methyllorazepam) administered intraperitoneally to rats rendered hyperlipidemic by Triton WR-1339 induced an elevation of blood glucose level at all investigated doses. It brought about significant reduction of serum total lipids, total cholesterol and triglycerides. The dose-response relationship was bell-shaped. However, it presented two peaks, differing from the responses to other benzodiazepines (BZD) which were characterized by only one peak.

Animals↗
PubMedDate not supplied

The effects of the intraperitoneal administration of midazolam on blood glucose level and serum lipids in streptozotocin-induced diabetes in rats.

In male Wistar rats rendered diabetic by streptozotocin administration, the intraperitoneal (i.p.) injection of midazolam (2.5-5.0 and 10 mg/kg) induced a significant reduction of hyperglycemia and hyperlipidemia. The plasma immunoreactive insulin level was slightly, but significantly increased. The lethality was diminished.

Animals↗